Evogene (NASDAQ: EVGN) cuts 2025 net loss to $7.8 million amid AI focus
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Evogene Ltd. reported 2025 results showing a smaller overall loss alongside a major strategic shift toward its ChemPass AI generative small‑molecule platform. Net loss for 2025 narrowed to approximately $7.8 million from about $18.1 million, mainly due to lower operating expenses and a $6.4 million gain on the sale of Lavie Bio and MicroBoost AI for Ag to ICL, recorded in $5.7 million of income from discontinued operations.
Full‑year revenues fell to roughly $3.9 million from $5.6 million as certain AgPlenus and Corteva revenues and Casterra seed sales declined. A $2.2 million Casterra inventory impairment pushed 2025 cost of revenues to about $4.1 million, driving an operating loss of $14.0 million. Cash, cash equivalents and short‑term deposits were about $13.0 million at year‑end, after using $13.5 million in operating cash during 2025, while management exited non‑core assets, resized the organization and highlighted new AI collaborations with Google Cloud in pharma and agriculture.
Positive
- Net loss reduced materially: 2025 net loss was approximately $7.8 million versus about $18.1 million in 2024, helped by lower operating expenses and $5.7 million income from discontinued operations, including a $6.4 million gain on the Lavie Bio and MicroBoost AI for Ag sale to ICL.
Negative
- Revenue decline and cash burn: 2025 revenues fell to about $3.9 million from $5.6 million, while Evogene used roughly $13.5 million in operating cash during 2025 and recorded a $14.0 million operating loss, indicating continued pressure on the core business and liquidity.
Insights
Loss narrows on cost cuts and asset sale, but revenue and cash remain pressure points.
Evogene reduced its 2025 net loss to approximately
Revenue declined to roughly
Year‑end cash, cash equivalents and short‑term deposits were about
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2026
Commission File Number: 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
On March 5, 2026, Evogene Ltd. (“Evogene”) announced its financial results for the fourth quarter and fiscal year ended December 31,
2025. A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) and is incorporated herein by reference.
Evogene is holding a conference call on March 5, 2026 to discuss its quarterly results for the quarter ended December 31, 2025 and, in connection with that call, will make
available to its investors a slide presentation to provide additional information regarding its business and its financial results. That slide presentation is attached as Exhibit 99.2 to this Form 6-K and is incorporated herein by reference.
The GAAP financial statements tables contained in the press release attached to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities
and Exchange Commission (“SEC”) File No. 333-277565), and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856, 333-259215, and 333-286197) of Evogene, and will be a part thereof from the date on which
this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Date: March 5, 2026 |
|
EVOGENE LTD.
(Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer |
EXHIBIT INDEX
|
EXHIBIT NO.
|
DESCRIPTION
|
|
99.1
|
Press Release: Evogene Reports Fourth Quarter and Full Year 2025 Financial Results.
|
|
99.2
|
Slide presentation for conference call of Evogene held on March 5, 2026, discussing
Evogene’s quarterly financial results for the fourth quarter of 2025.
|
Exhibit 99.1
Evogene Reports Fourth Quarter and Full Year 2025 Financial Results
Conference call and webcast: today, March 05, 2026, 9:00 AM ET
Rehovot, Israel – March 5, 2026 – Evogene Ltd. (Nasdaq, TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design
of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
Mr. Ofer Haviv, President & CEO of Evogene, stated: “During 2025, we executed a clear and decisive strategic shift. After a comprehensive review of our
technology assets, target markets, and capital allocation priorities, we sharpened our focus to drive sustainable long-term value by concentrating on a single proprietary tech-engine - ChemPass AI™- for small-molecule discovery and optimization. We
streamlined our operations to focus on two high-impact markets: pharma and agriculture, while discontinuing non-core activities, divesting misaligned assets, resizing the organization, and aligning our business development efforts with this focused
strategy. ChemPass AI™’s competitive advantage combines two core strengths: generating truly novel molecules and simultaneously optimizing multiple critical parameters from the outset.
Throughout 2025, ChemPass AI™ was advanced through proprietary internal developments and strategic collaborations with Google Cloud. Our first collaboration delivered a foundation model trained on 38
billion structures, achieving 90% design precision, based on our calculation - approximately tripling our benchmarks for accuracy. A second collaboration, launched in February 2026, integrates AI agents via Google Cloud Vertex AI to automate
workflows, reduce manual errors, and further strengthen candidate quality and commercial potential.
Evogene’s offering - our proprietary small-molecule product candidates - combines three unique powerful characteristics: novel molecules representing new and diverse chemical structures; optimized
for simultaneous multi-parameters from the earliest design stages; and highly potent compounds refined through targeted experimental validation.
Our business model is built on an integrated, partnership-driven approach that supports both collaborations and the in-house advancement of proprietary candidates. Projects begin with joint strategic
alignment and continue through rigorous experimental validation, with partners actively engaged at every stage and programs tailored to specific scientific and commercial objectives.
In pharma, since the second half of 2025, we have advanced multiple partnered drug discovery programs, with ChemPass AI™ candidates progressing into experimental testing by our partners; four
collaborations have been publicly disclosed to date.
In agriculture, AgPlenus applies ChemPass AI™ to novel herbicide and fungicide development, supported by strategic collaborations with Bayer and Corteva and a differentiated internal pipeline,
positioning us for continued growth.”
Mr. Haviv continued: “As part of our focused strategy, we discontinued non-core activities, divested misaligned assets, and resized the organization. During
2025, Lavie Bio was acquired by ICL. In early 2026, Biomica licensed its lead oncology candidate, BMC128, to Lishan Pharmaceuticals. No additional activity is expected from these companies. At the same time, Evogene has retained select activities
with meaningful value potential that are not at the core of our new strategy, including Casterra, and intends to continue supporting these activities until their full potential is realized.
Looking ahead, the advancement of proprietary small-molecule product candidates is at the heart of Evogene’s mission. Supported by ChemPass AI™, our differentiated generative AI tech-engine,
disciplined capital allocation across two high-potential markets, and strong strategic partnerships, we believe Evogene is well-positioned on a clearly defined and focused path toward sustainable long-term value creation.”
Financial Highlights:
| ● |
As part of the Company’s updated strategic plan, management implemented an organizational realignment and cost-reduction initiative. The effects of these measures are reflected in the significant decrease in operating expenses, net, which
declined to approximately $13.8 million for the year ended 2025, compared to approximately $22.0 million in 2024. The impact is also evident in the fourth-quarter results, with total operating expenses, net, of approximately $3.2 million,
compared to approximately $4.3 million in the corresponding period of 2024. The Company expects this reduced expense level to be sustained in future periods.
|
| ● |
In 2025, Lavie Bio, our subsidiary focused on agricultural biologicals, completed the sale of the majority of its operations to ICL Group Ltd. As a result of this transaction, Lavie Bio no longer maintains employees, and its operating
expense level has decreased significantly. Lavie Bio anticipates distributing the majority of its remaining cash to its shareholders, including Evogene, during 2026.
|
| ● |
During 2025, as part of the Company’s updated strategic plan, we scaled down Biomica’s operations and research and development activities and reduced its personnel to a minimal level. In early 2026, Biomica entered into a license agreement
with Lishan Pharmaceuticals for its lead oncology candidate, BMC128. Following this transaction, Biomica does not expect to conduct further material operational activities and anticipates distributing the majority of its remaining cash to its
shareholders, including Evogene.
|
| ● |
With respect to AgPlenus, we integrated AgPlenus, our ag-chemical subsidiary, into our core operations, with the objective of maximizing the value of our ChemPass AI platform for the development of novel ag-chemical products. In alignment
with the Company’s updated organizational structure, AgPlenus was resized and streamlined to reflect the revised operating model.
|
| ● |
During 2025, due to a significant decline in demand for castor seeds, Casterra Ag ceased its operations in Kenya, reduced its headcount and overall expense level, and is currently focusing its activities on the Brazilian market. As a
result of these developments, Casterra recorded an impairment of approximately $2.2 million related to its seed inventory. This impairment is presented within Cost of Sales in the consolidated financial statements in a separate line item.
|
| ● |
In February 2026, we entered into a warrant inducement agreement with an existing investor providing for the immediate exercise in full of its August 2024 Series A and Series B warrants, resulting in gross proceeds to the Company of
approximately $3.4 million, before deduction of placement agent fees and other offering expenses. In consideration for such exercise, the investor will receive, in a private placement, new unregistered Series A-1 and Series B-1 warrants to
purchase up to an aggregate of 5,076,924 ordinary shares. The new warrants are exercisable immediately at an exercise price of $1.25 per ordinary share.
|
Financial reports:
Cash Position - As of December 31, 2025, Evogene held consolidated cash, cash equivalents, and short-term bank deposits of approximately $13.0 million. The
consolidated cash usage during the fourth quarter of 2025 was approximately $3.0 million. Excluding Lavie Bio and Biomica, Evogene and its other subsidiaries used approximately $2.4 million in cash during the fourth quarter of 2025.
Revenues for 2025 totaled approximately $3.9 million, compared to approximately $5.6 million in the same period the previous year, reflecting a decrease of
approximately $1.7 million. The decrease was primarily driven by lower revenue recognized from AgPlenus’ activity, which included one-time payment during the first quarter of 2024 and revenues recognized from the collaboration agreement with Corteva,
that was completed during 2024. Revenues for the fourth quarter of 2025 were approximately $0.3 million; a decrease compared to approximately $1.5 million in the same period last year. The decrease was mainly due to reduced seed sales generated by
Casterra during the fourth quarter of 2025.
Cost of Revenues for the year ending 2025 was approximately $4.1 million, compared to approximately $2.4 million in the previous year. The increase was
primarily attributable to an inventory impairment of approximately $2.2 million recorded by Casterra during the fourth quarter of 2025 mainly due to its decision to cease its operations in Kenya as noted above. Cost of revenues for the fourth quarter
of 2025 was $2.3 million, compared to $0.7 million in the fourth quarter of the previous year. The increase in quarterly cost of revenues was mainly driven by the same inventory impairment of Casterra as noted above.
R&D Expenses, net of non-refundable grants, for the year 2025 were approximately $8.0 million, a decrease of approximately $4.5 million compared to $12.5
million in the year 2024. The decrease was primarily due to reduced R&D expenses in Biomica, Casterra and AgPlenus. In the fourth quarter of 2025, R&D expenses were approximately $1.8 million, down from approximately $2.7 million in the same
period of 2024. This decrease is mainly attributed to decreased expenses in Biomica.
Sales and Marketing Expenses for the year 2025 were approximately $1.5 million, a decrease of approximately $0.5 million compared to approximately $2.0 million
in the same period last year. The decrease was mainly due to reductions in Evogene and Biomica personnel costs. Sales and marketing expenses for the fourth quarters of 2025 and 2024 were approximately $0.3 million and $0.4 million, respectively.
General and Administrative Expenses for the year 2025 decreased to approximately $4.3 million from approximately $7.0 million in the same period last year.
This decrease is mainly attributable to expenses recorded during the year 2024 related to a provision for doubtful debt for one of Casterra’s seed suppliers as well as transaction costs associated with Evogene’s fundraising in August 2024. Additional
decrease is attributable to a reduction in Biomica’s activities and personnel costs during 2025. General and administrative expenses for the fourth quarter of 2025 decreased to approximately $0.9 million compared to approximately $1.3 million in the
same period of the previous year, primarily due to decreased expenses in Evogene and Biomica, as mentioned above.
Other Expenses, net of approximately $37 thousand were recorded in 2025 mainly due to the impairment of fixed assets associated with the reduction in Biomica’s
activities, partially offset by income recognized in the first quarter of 2025 related to the accounting treatment of Evogene’s sub-lease agreement. The decision to cease Canonic’s operations in the first half of 2024 resulted in other expenses of
approximately $0.5 million, primarily due to the impairment of fixed assets.
Operating Loss for 2025 was approximately $14.0 million, a significant decrease from approximately $18.8 million in the same period of the previous year,
mainly due to decreased operating expenses, partially offset by the decreased revenues as mentioned above and the higher cost of revenues, mainly due to an inventory impairment of approximately $2.2 million recorded by Casterra, in the fourth quarter
of 2025. The operating loss for the fourth quarter of 2025 was approximately $5.2 million, an increase from approximately $3.5 million in the same period of the previous year, primarily due to the decreased revenues and increased cost of revenues,
mentioned above, partially offset by decreased operating expenses.
Financing Income, net for the year 2025 was approximately $0.6 million, compared to approximately $4.0 million in the previous year. The decrease in financing
income, net was mainly associated with accounting treatment of pre-funded warrants and warrants issued in August 2024 fund raising. As a result, during the twelve months of 2025 the Company recorded financial income, net, related to pre-funded
warrants and warrants of approximately $458 thousand as compared to a financial income of approximately $3.4 million in same period of 2024. Financing expenses, net, for the fourth quarter of 2025 were approximately $0.2 million, compared to
financing income, net of approximately $4.5 million in the same period of the previous year. The decrease in financing income is mainly associated with accounting treatment of pre-funded warrants and warrants issued in the August 2024 fund raising as
mentioned above.
Income from Discontinued Operations, net for the twelve months of 2025 was approximately $5.7 million, compared to a loss of approximately $3.2 million in the same period of
2024. For the fourth quarter of 2025, loss from discontinued operations, net was approximately $16 thousand, compared to a loss of approximately $1.0 million in the fourth quarter of the previous year. These amounts primarily reflect the financial
results of Lavie Bio’s operations as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single-line item in the consolidated statements of profit and loss. Following the sale of the
majority of Lavie Bio’s assets as well as Evogene’s MicroBoost AI for Ag to ICL, the Company recognized a gain on sale of approximately $6.4 million which is also included in the income (loss) from discontinued operations, net, for the year of
2025. All prior period amounts have been reclassified to conform to this presentation.
Net loss for the twelve months of 2025 was approximately $7.8 million, compared to approximately $18.1 million in the same period last year. The $10.3 million decrease in net
loss was primarily due to decreased operating expenses and an income derived from discontinued operations due to the asset sale to ICL, net, partially offset by reduced revenues, higher cost of revenues and a decreased financing income, net. The
net loss for the fourth quarter of 2025 was approximately $5.4 million, compared to net loss of approximately $5 thousand in the same period last year. This increase in net loss was primarily due to decreased financial income, net, decreased
revenues, and increased cost of revenues, partially offset by decreased operating expenses, as mentioned above.
About Evogene Ltd.
Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the
pharmaceutical and agricultural industries.
At the core of its technology is ChemPass AI™, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized
across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs.
Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the
integration of scientific innovation with real-world industry needs. We call this approach "Real-World Innovation."
Learn more at: www.evogene.com.
Forward-Looking Statements
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as “may,” “could,” “expects,”
“hopes,” “intends,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates,” “demonstrates” or words of similar meaning. For example, Evogene is using forward-looking statements in this press release when it discusses ChemPass AI™’s competitive advantage, the potential success of Evogene’s proprietary small-molecule product candidates, the potential success of Evogene’s collaboration with third parties, Casterra’s potential, Evogene’s
potential to create value. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not
guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors,
many of which are beyond the control of Evogene, including, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional
terrorist groups supported by Iran, and any destabilizations in Israel, neighboring territories or the Middle East region, as well as those additional risk factors identified those risk factors contained in Evogene’s reports filed with the
applicable securities authority. In addition, Evogene rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry
out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or
commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Evogene Investor Relations Contact:
Email: ir@evogene.com
Tel: +972-8-9311901
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
U.S. dollars in thousands
|
December 31,
|
December 31,
|
|||||||
|
2025
|
2024
|
|||||||
|
CURRENT ASSETS:
|
||||||||
|
Cash and cash equivalents
|
$
|
12,956
|
$
|
15,301
|
||||
|
Restricted cash
|
32
|
10
|
||||||
|
Trade receivables
|
317
|
1,091
|
||||||
|
Other receivables and prepaid expenses
|
1,565
|
2,064
|
||||||
|
Deferred expenses related to issuance of warrants
|
551
|
1,304
|
||||||
|
Inventories
|
210
|
1,819
|
||||||
|
15,631
|
21,589
|
|||||||
|
LONG-TERM ASSETS:
|
||||||||
|
Long-term deposits and other receivables
|
571
|
12
|
||||||
|
Investment accounted for using the equity method
|
43
|
82
|
||||||
|
Deferred expenses related to issuance of warrants
|
1,165
|
1,735
|
||||||
|
Right-of-use-assets
|
1,824
|
2,447
|
||||||
|
Property, plant and equipment, net
|
812
|
1,804
|
||||||
|
Intangible assets, net
|
-
|
12,195
|
||||||
|
4,415
|
18,275
|
|||||||
|
$
|
20,046
|
$
|
39,864
|
|||||
|
CURRENT LIABILITIES:
|
||||||||
|
Trade payables
|
$
|
639
|
$
|
1,228
|
||||
|
Employees and payroll accruals
|
861
|
1,869
|
||||||
|
Lease liability
|
716
|
589
|
||||||
|
Liabilities in respect of government grants
|
56
|
323
|
||||||
|
Deferred revenues and other advances
|
17
|
360
|
||||||
|
Warrants and pre-funded warrants liability
|
706
|
2,876
|
||||||
|
Convertible SAFE
|
-
|
10,371
|
||||||
|
Other payables
|
449
|
1,079
|
||||||
|
3,444
|
18,695
|
|||||||
|
LONG-TERM LIABILITIES:
|
||||||||
|
Lease liability
|
1,482
|
1,914
|
||||||
|
Liabilities in respect of government grants
|
3,073
|
4,327
|
||||||
|
Deferred revenues and other advances
|
72
|
90
|
||||||
|
4,627
|
6,331
|
|||||||
|
SHAREHOLDERS' EQUITY:
|
||||||||
|
Ordinary shares of NIS 0.2 par value:
Authorized – 30,000,000 ordinary shares; Issued and outstanding – 8,718,193 shares on December 31, 2025 and 6,514,589 shares on December 31, 2024
|
488
|
363
|
||||||
|
Share premium and other capital reserve
|
281,986
|
272,257
|
||||||
|
Accumulated deficit
|
(282,556
|
)
|
(274,071
|
)
|
||||
|
Equity attributable to equity holders of the Company
|
(82
|
)
|
(1,451
|
)
|
||||
|
Non-controlling interests
|
12,057
|
16,289
|
||||||
|
Total equity
|
11,975
|
14,838
|
||||||
|
$
|
20,046
|
$
|
39,864
|
|||||
CONSOLIDATED STATEMENTS OF PROFIT OR LOSS
U.S. dollars in thousands (except share and per share amounts)
|
Year ended
December 31,
|
Three months ended
December 31,
|
|||||||||||||||
|
2025
|
2024 (*)
|
|
2025
|
2024 (*)
|
|
|||||||||||
|
Revenues
|
$
|
3,853
|
$
|
5,577
|
$
|
314
|
$
|
1,543
|
||||||||
|
Cost of Revenues:
|
||||||||||||||||
|
Inventory impairment
|
2,180
|
-
|
2,180
|
-
|
||||||||||||
|
Other cost of revenues
|
1,914
|
2,380
|
104
|
692
|
||||||||||||
|
Total Cost of Revenues
|
4,094
|
2,380
|
2,284
|
692
|
||||||||||||
|
Gross profit (loss)
|
(241
|
)
|
3,197
|
(1,970
|
)
|
851
|
||||||||||
|
Operating expenses (income):
|
||||||||||||||||
|
Research and development, net
|
7,994
|
12,511
|
1,827
|
2,707
|
||||||||||||
|
Sales and marketing
|
1,476
|
1,983
|
298
|
351
|
||||||||||||
|
General and administrative
|
4,286
|
6,993
|
898
|
1,283
|
||||||||||||
|
Other expenses (income)
|
37
|
514
|
219
|
(10
|
)
|
|||||||||||
|
Total operating expenses, net
|
13,793
|
22,001
|
3,242
|
4,331
|
||||||||||||
|
Operating loss
|
(14,034
|
)
|
(18,804
|
)
|
(5,212
|
)
|
(3,480
|
)
|
||||||||
|
Financing income
|
2,466
|
7,393
|
181
|
4,734
|
||||||||||||
|
Financing expenses
|
(1,891
|
)
|
(3,358
|
)
|
(350
|
)
|
(251
|
)
|
||||||||
|
Financing income (expenses), net
|
575
|
4,035
|
(169
|
)
|
4,483
|
|||||||||||
|
Share of loss (gain) of an associate
|
39
|
39
|
(43
|
)
|
13
|
|||||||||||
|
Gain (loss) before taxes on income
|
(13,498
|
)
|
(14,808
|
)
|
(5,338
|
)
|
990
|
|||||||||
|
Taxes on income
|
1
|
9
|
-
|
7
|
||||||||||||
|
Income (loss) from continuing operations
|
(13,499
|
)
|
(14,817
|
)
|
(5,338
|
)
|
983
|
|||||||||
|
Income (loss) from discontinued operations, net
|
5,672
|
(3,237
|
)
|
(16
|
)
|
(988
|
)
|
|||||||||
|
Loss
|
$
|
(7,827
|
)
|
$
|
(18,054
|
)
|
$
|
(5,354
|
)
|
$
|
(5
|
)
|
||||
|
Attributable to:
|
||||||||||||||||
|
Equity holders of the Company
|
(8,485
|
)
|
(16,485
|
)
|
(5,309
|
)
|
427
|
|||||||||
|
Non-controlling interests
|
658
|
(1,569
|
)
|
(45
|
)
|
(432
|
)
|
|||||||||
|
$
|
(7,827
|
)
|
$
|
(18,054
|
)
|
$
|
(5,354
|
)
|
$
|
(5
|
)
|
|||||
|
Basic and diluted gain (loss) per share from continuing operations, attributable to equity holders of the Company
|
$
|
(1.70
|
)
|
$
|
(2.47
|
)
|
$
|
(0.61
|
)
|
$
|
0.17
|
|||||
|
Basic and diluted gain (loss) per share from discontinued operations, attributable to equity holders of the Company
|
$
|
0.62
|
$
|
(0.43
|
)
|
$
|
(0.002
|
)
|
$
|
(0.11
|
)
|
|||||
|
Weighted average number of shares used in computing basic and diluted loss per share
|
7,874,039
|
5,697,245
|
8,718,207
|
6,795,589
|
||||||||||||
(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.
CONSOLIDATED STATEMENTS OF CASH FLOS
U.S. dollars in thousands
|
Year ended
December 31,
|
Three months ended
December 31,
|
|||||||||||||||
|
2025
|
2024 (*)
|
2025
|
2024 (*)
|
|||||||||||||
|
Cash flows from operating activities:
|
||||||||||||||||
|
Loss from continuing operations
|
$
|
(13,499
|
)
|
$
|
(14,817
|
)
|
$
|
(5,338
|
)
|
$
|
983
|
|||||
|
Adjustments to reconcile loss to net cash used in operating activities:
|
||||||||||||||||
|
Adjustments to the profit or loss items:
|
||||||||||||||||
|
Depreciation of property, plant and equipment and right-of-use-assets
|
1,144
|
1,381
|
263
|
441
|
||||||||||||
|
Share-based compensation
|
654
|
1,243
|
155
|
263
|
||||||||||||
|
Remeasurement of Convertible SAFE
|
(371
|
)
|
3
|
-
|
51
|
|||||||||||
|
Net financing expenses (income)
|
(28
|
)
|
(771
|
)
|
(49
|
)
|
(1,013
|
)
|
||||||||
|
Loss (gain) from sale of property, plant and equipment
|
(209
|
)
|
525
|
(27
|
)
|
2
|
||||||||||
|
Impairment of property, plant and equipment
|
246
|
-
|
246
|
-
|
||||||||||||
|
Inventory impairment
|
2,180
|
-
|
2,180
|
-
|
||||||||||||
|
Revaluation of government grants
|
40
|
-
|
16
|
-
|
||||||||||||
|
Excess of initial fair value of pre-funded warrants over transaction proceeds
|
-
|
2,684
|
-
|
-
|
||||||||||||
|
Amortization of deferred expenses related to issuance of warrants
|
1,323
|
471
|
334
|
334
|
||||||||||||
|
Remeasurement of pre-funded warrants and warrants
|
(1,781
|
)
|
(6,529
|
)
|
(117
|
)
|
(4,589
|
)
|
||||||||
|
Share of loss of an associate
|
39
|
39
|
(43
|
)
|
13
|
|||||||||||
|
Taxes on income (tax benefit)
|
(6
|
)
|
9
|
(7
|
)
|
7
|
||||||||||
|
3,231
|
(945
|
)
|
2,951
|
(4,491
|
)
|
|||||||||||
|
Changes in asset and liability items:
|
||||||||||||||||
|
Decrease (increase) in trade receivables
|
665
|
(627
|
)
|
(2
|
)
|
601
|
||||||||||
|
Decrease (increase) in other receivables and prepaid expenses
|
1,047
|
806
|
87
|
248
|
||||||||||||
|
Decrease (increase) in inventories
|
(1,019
|
)
|
(1,277
|
)
|
(279
|
)
|
(380
|
)
|
||||||||
|
Increase (decrease) in trade payables
|
(259
|
)
|
(630
|
)
|
188
|
(166
|
)
|
|||||||||
|
Increase (decrease) in employees and payroll accruals
|
(756
|
)
|
(548
|
)
|
(192
|
)
|
(397
|
)
|
||||||||
|
Increase (decrease) in other payables
|
(570
|
)
|
222
|
(30
|
)
|
162
|
||||||||||
|
Increase (decrease) in deferred revenues and other advances
|
(361
|
)
|
(559
|
)
|
(5
|
)
|
(463
|
)
|
||||||||
|
(1,253
|
)
|
(2,613
|
)
|
(233
|
)
|
(395
|
)
|
|||||||||
|
Cash received (paid) during the period for:
|
||||||||||||||||
|
Interest received
|
338
|
934
|
117
|
398
|
||||||||||||
|
Interest paid
|
(193
|
)
|
(67
|
)
|
(43
|
)
|
(10
|
)
|
||||||||
|
Taxes paid
|
(11
|
)
|
(11
|
)
|
-
|
(11
|
)
|
|||||||||
|
Net cash used in continuing operating activities
|
||||||||||||||||
|
(11,387
|
)
|
(17,519
|
)
|
(2,546
|
)
|
(3,526
|
)
|
|||||||||
|
Net cash used in operating activities of discontinued operations
|
(2,115
|
)
|
(2,181
|
)
|
(140
|
)
|
(1,035
|
)
|
||||||||
|
Net cash used in operating activities
|
(13,502
|
)
|
(19,700
|
)
|
(2,686
|
)
|
(4,561
|
)
|
||||||||
(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.
CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
|
Year ended
December 31,
|
Three months ended
December 31,
|
|||||||||||||||
|
2025
|
2024 (*)
|
|
2025
|
2024 (*)
|
|
|||||||||||
|
Cash flows from investing activities:
|
||||||||||||||||
|
Purchase of property, plant and equipment
|
(135
|
)
|
(626
|
)
|
(6
|
)
|
(322
|
)
|
||||||||
|
Proceeds from sale of property, plant and equipment
|
78
|
10
|
47
|
-
|
||||||||||||
|
Proceeds from finance sub-lease asset
|
52
|
-
|
23
|
-
|
||||||||||||
|
Withdrawal from (investment in) bank deposits, net
|
(1
|
)
|
10,190
|
7,399
|
7,773
|
|||||||||||
|
Net cash provided by (used in) continuing investing activities
|
(6
|
)
|
9,574
|
7,463
|
7,451
|
|||||||||||
|
Net cash provided by investing activities of discontinued operations
|
17,744
|
48
|
2,800
|
1,307
|
||||||||||||
|
Net cash provided by investing activities
|
17,738
|
9,622
|
10,263
|
8,758
|
||||||||||||
|
Cash flows from financing activities:
|
||||||||||||||||
|
Proceeds from issuance of ordinary shares, pre-funded warrants and warrants
|
-
|
5,500
|
-
|
-
|
||||||||||||
|
Proceeds from issuance of ordinary shares, net of issuance expenses
|
4,283
|
123
|
-
|
-
|
||||||||||||
|
Repayment of lease liability
|
(526
|
)
|
(886
|
)
|
(133
|
)
|
(310
|
)
|
||||||||
|
Proceeds from government grants
|
-
|
134
|
-
|
|||||||||||||
|
Repayment of convertible SAFE
|
(10,000
|
)
|
-
|
-
|
-
|
|||||||||||
|
Repayment of government grants
|
(244
|
)
|
(298
|
)
|
(122
|
)
|
-
|
|||||||||
|
Net cash provided by (used in) continuing financing activities
|
(6,487
|
)
|
4,573
|
(255
|
)
|
(310
|
)
|
|||||||||
|
Net cash provided by (used in) financing activities of discontinued operations
|
(115
|
)
|
83
|
(1
|
)
|
104
|
||||||||||
|
Net cash provided by (used in) financing activities
|
(6,602
|
)
|
4,656
|
(256
|
)
|
(206
|
)
|
|||||||||
|
Exchange rate differences - cash and cash equivalent balances
|
21
|
(49
|
)
|
9
|
(7
|
)
|
||||||||||
|
Increase (decrease) in cash and cash equivalents
|
(2,345
|
)
|
(5,471
|
)
|
7,330
|
3,984
|
||||||||||
|
Cash and cash equivalents, beginning of the period
|
15,301
|
20,772
|
5,626
|
11,317
|
||||||||||||
|
Cash and cash equivalents, end of the period
|
$
|
12,956
|
$
|
15,301
|
$
|
12,956
|
$
|
15,301
|
||||||||
(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.
|
Year ended
December 31,
|
Three months ended
December 31,
|
|||||||||||||||
|
2025
|
2024
|
2025
|
2024
|
|||||||||||||
|
Acquisition of property, plant and equipment
|
2
|
120
|
-
|
120
|
||||||||||||
|
Increase of right-of-use-asset recognized with corresponding lease liability
|
207
|
2,307
|
-
|
-
|
||||||||||||
|
Exercise of pre-funded warrants
|
389
|
2,289
|
-
|
2,289
|
||||||||||||
|
Derecognition of property, plant and equipment under a finance lease
|
13
|
-
|
-
|
-
|
||||||||||||
|
Investment in affiliated Company with corresponding deferred revenues
|
120
|
-
|
-
|
|||||||||||||
Exhibit 99.2
FAQ
How did Evogene Ltd. (EVGN) perform financially in 2025?
Evogene reduced its 2025 net loss to approximately $7.8 million from about $18.1 million in 2024. The improvement came mainly from lower operating expenses and $5.7 million income from discontinued operations, partly offset by weaker revenues and higher cost of revenues, including a Casterra inventory impairment.
What were Evogene’s revenues and operating loss for 2025?
Evogene generated approximately $3.9 million in revenues in 2025, down from about $5.6 million a year earlier, mainly due to lower AgPlenus, Corteva, and Casterra contributions. Operating loss was roughly $14.0 million versus $18.8 million in 2024, reflecting cost reductions but also higher cost of revenues.
What is Evogene’s cash position and cash usage as of December 31, 2025?
As of December 31, 2025, Evogene held about $13.0 million in consolidated cash, cash equivalents and short‑term bank deposits. Net cash used in operating activities was roughly $13.5 million for 2025 and about $2.7 million in the fourth quarter, highlighting ongoing cash burn despite strategic streamlining.
How did discontinued operations impact Evogene’s 2025 results?
Income from discontinued operations, net, was approximately $5.7 million in 2025 versus a $3.2 million loss in 2024. This mainly reflects Lavie Bio’s results and the sale of Lavie Bio’s assets and MicroBoost AI for Ag to ICL, which generated a $6.4 million gain for Evogene.
What strategic changes did Evogene implement around ChemPass AI in 2025?
Evogene refocused on a single proprietary generative AI engine, ChemPass AI™, for small‑molecule discovery in pharma and agriculture. It discontinued non‑core activities, divested misaligned assets like Lavie Bio, resized the organization, and advanced collaborations, including foundation and AI‑agent projects with Google Cloud.
How did Evogene’s research and development spending change in 2025?
Research and development expenses, net of non‑refundable grants, decreased to about $8.0 million in 2025 from roughly $12.5 million in 2024. The reduction mainly reflects lower R&D spending at Biomica, Casterra, and AgPlenus as Evogene streamlined activities around its ChemPass AI strategy.
Filing Exhibits & Attachments
2 documentsPress Releases
Evogene
NASDAQ:EVGN
EVGN Rankings
EVGN Latest News
Feb 25, 2026
Evogene Releases CEO Letter to Shareholders
EVGN Latest SEC Filings
Feb 25, 2026
[6-K] Evogene Ltd. Current Report (Foreign Issuer)
Feb 11, 2026
[6-K] Evogene Ltd. Current Report (Foreign Issuer)
Jan 15, 2026
[6-K] Evogene Ltd. Current Report (Foreign Issuer)
Nov 20, 2025
[6-K] Evogene Ltd. Current Report (Foreign Issuer)